These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 590850)

  • 21. The use of calcium chelating agents and prostaglandin E to eliminate platelet and white blood cell losses resulting from hemoperfusion through uncoated charcoal, albumin-agarose gel, and neutral and cation exchange resins.
    Scharschmidt BF; Martin JF; Shapiro LJ; Plotz PH; Berk PD
    J Lab Clin Med; 1977 Jan; 89(1):110-9. PubMed ID: 401516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of charcoal haemoperfusion on platelet count in acute poisoning and during regular dialysis treatment.
    Mydlík M; Bucek J; Derzsiová K; Jarcuska J; Takác M
    Int Urol Nephrol; 1981; 13(4):387-9. PubMed ID: 7343540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro evaluation of adsorbents used in haemoperfusion (author's transl)].
    Külpmann WR; Oellerich M; Blume U; Schmidt E; Barthels M
    Klin Wochenschr; 1978 Dec; 56(23):1171-8. PubMed ID: 30857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of an in vitro haemoperfusion circuit to evaluate the blood compatibility of albumin-coated Amberlite XAD-7 resin.
    Hughes RD; Ton HY; Langley PG; Silk DB; Williams R
    Int J Artif Organs; 1978 May; 1(3):129-34. PubMed ID: 689755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmaphoresis, charcoal, and resin perfusion in experimental porcine hepatic failure.
    Alp MH; Hickman R
    Dig Dis Sci; 1986 Feb; 31(2):181-7. PubMed ID: 3943446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of charcoal hemoperfusion with prostacyclin on the coagulation-fibrinolysis system and platelets of patients with fulminant hepatic failure--preliminary observations.
    Cordopatri F; Boncinelli S; Marsili M; Lorenzi P; Fabbri LP; Paci P; Salvadori M; Morfini M; Cinotti S; Casparini P
    Int J Artif Organs; 1982 Jul; 5(4):243-7. PubMed ID: 6749697
    [No Abstract]   [Full Text] [Related]  

  • 27. [Changes in platelet function in liver diseases].
    Castillo R; Casals FJ; Maragall S; Rodés J; Ordinas A
    Sangre (Barc); 1982; 27(4-B):672-9. PubMed ID: 7157140
    [No Abstract]   [Full Text] [Related]  

  • 28. Haemoperfusion through activated charcoal in dogs with fulminant liver failure.
    Horák J; Horký J; Rábl M
    Digestion; 1980; 20(1):22-30. PubMed ID: 7353731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of serum alpha-fetoprotein in fulminant hepatic failure including patients treated by charcoal haemoperfusion.
    Murray-Lyon IM; Orr AH; Gazzard B; Kohn J; Williams R
    Gut; 1976 Aug; 17(8):576-80. PubMed ID: 61904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Charcoal hemoperfusion for liver failure.
    Weston MJ
    Lancet; 1982 Oct; 2(8305):983. PubMed ID: 6127478
    [No Abstract]   [Full Text] [Related]  

  • 31. Haematological changes induced by direct contact over a coated activated charcoal: in vivo and in vitro study.
    Mazzarella V; Taccone-Gallucci M; Meloni C; Morosetti M; Verardi S; Ferri GM; Caccavo D; Casciani CU
    Life Support Syst; 1984; 2(2):113-9. PubMed ID: 6482504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
    Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
    Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis.
    Silk DB; Williams R
    Int J Artif Organs; 1978 Jan; 1(1):29-33. PubMed ID: 669832
    [No Abstract]   [Full Text] [Related]  

  • 34. Acid citrate dextrose reduces platelet retention during in vitro and in vivo dog hemoperfusion: a comparative study of different charcoal adsorbers.
    Tangerman A; Snel P; van Schaik A; van Tongeren JH
    Artif Organs; 1981 Nov; 5(4):357-62. PubMed ID: 7325877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with the use of charcoal haemoperfusion: is prostacyclin required?
    Kennedy HJ; Greaves M; Triger DR
    Life Support Syst; 1985; 3(2):115-22. PubMed ID: 3894813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Charcoal hemoperfusion for chronic renal failure.
    Siemsen AW; Dunea G; Mamdani BH; Guruprakash G
    Nephron; 1978; 22(4-6):386-90. PubMed ID: 740102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New apparatus for artificial liver support: PAT resin--removal of protein-bound substances and its effect on hepatic failure in animals].
    Omori Y
    Nihon Geka Gakkai Zasshi; 1985 May; 86(5):566-75. PubMed ID: 4021990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of serial resin hemoperfusion in fulminant hepatic failure.
    Bihari D; Hughes RD; Gimson AE; Langley PG; Ede RJ; Eder G; Williams R
    Int J Artif Organs; 1983 Nov; 6(6):299-302. PubMed ID: 6668092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment.
    Chirito E; Lister C; Chang TM
    Artif Organs; 1979 Feb; 3(1):42-6. PubMed ID: 435123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of artificial liver support.
    Williams R; Ede R; Hughes R
    Int J Clin Pharmacol Res; 1985; 5(6):381-7. PubMed ID: 3005180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.